Ligand Pharmaceuticals (LGND) reported $268M in revenue for fiscal 2025, +60.4% year on year. That ranks #2543 by revenue among 2853 SEC filers and #259 in Healthcare. Net income was $124M, a net margin of 46.4%. Revenue has grown 16.9% a year on average since 2011 ($30.0M then). The fiscal 2025 balance sheet shows $1.6B in total assets, $175M in cash and $27.5M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $268M | +60.4% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $41.0M | +$63.6M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $124M | +$128M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $49.4M | −49.1% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $452,000 | −75.2% | FY20252025-12-31 |
| Total assetsAssets | $1.6B | +65.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.0B | +22.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $175M | +141.9% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $27.5M | — | FY20122012-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $51.7M | −$13.3M | Open → |
| Q2 20262026-06-30 | $63.7M | $48.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Ligand Pharmaceuticals Inc
- Ticker
- LGND
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000886163
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| HarrowHROW | $272M | −$5.1M |
| Viemed HealthcareVMD | $270M | $15.4M |
| Vireo GrowthVREOF | $269M | −$68.1M |
| Ligand PharmaceuticalsLGND | $268M | $124M |
| Iovance BiotherapeuticsIOVA | $264M | −$391M |
| Jushi HoldingsJUSH | $263M | −$68.6M |
| ArvinasARVN | $263M | −$81.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ligand Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/ligand-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ligand Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/ligand-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-ligand-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Ligand Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ligand-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000886163-26-000006 · February 27, 2026
{{cite web |title=Ligand Pharmaceuticals — Key figures — 10-K (0000886163-26-000006) |url=https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/lgnd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.